

**DEPRESSION AND CARDIOVASCULAR AUTONOMIC CONTROL:
A MATTER OF VAGUS AND SEX PARADOX**

Eleonora Tobaldini^{a,b*}, Angelica Carandina^{a,d*}, Edgar Toschi-Dias^{a,b,c}, Luca Erba^{a,b}, Ludovico Furlan^{a,b}, Andrea Sgoifo^d, Nicola Montano^{a,b}.

^a Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy

^b Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

^c Laboratory of Autonomic and Cognitive Neuroscience - Methodist University of São Paulo, São Paulo, Brazil; Ibirapuera University, São Paulo, Brazil.

^d Department of Chemistry, Life Sciences and Environmental Sustainability, Stress Physiology Lab, University of Parma, Parma, Italy

*both authors equally contributed to the manuscript

Author for correspondence:

Nicola Montano, MD PhD

Ospedale Maggiore Policlinico

Via Francesco Sforza, 28

Milan - Italy

e-mail: nicola.montano@unimi.it

ABSTRACT

Depression is a well-established stress-related risk factor for several diseases, mainly for those with cardiovascular outcomes. The mechanisms that link depression disorders with cardiovascular diseases (CVD) include dysfunctions of the autonomic nervous system. Heart rate variability analysis is a widely-used non-invasive method that can simultaneously quantify the activity of the two branches of cardiac autonomic neural control and provide insights about their pathophysiological alterations. Recent scientific literature suggests that sex influences the relationship between depressive symptoms and cardiac autonomic dysfunction. Moreover, a few studies highlight a possible sex paradox: depressed women, despite a greater vagal tone, experience a higher risk of adverse cardiovascular events than depressed men. Although there are striking sex differences in the incidence of depression, scanty data on this topic are available. Lastly, studies on the heart-brain axis bidirectionality and the role of sex are fundamental not only to clarify the biological bases of depression-CVD comorbidity, but also to develop alternative therapies, where vagus nerve appears to be a promising target of non-invasive neuromodulation techniques.

Keywords: Depression, Cardiac autonomic control, Heart rate variability, Sex differences, Neuromodulation, Vagal stimulation

1 **CONTENTS**

2

3 **1. INTRODUCTION** 3

4 **2. CARDIAC AUTONOMIC CONTROL IN DEPRESSION**..... 5

5 **2.1. SEX DIFFERENCES IN THE RELATIONSHIP BETWEEN HRV AND DEPRESSION**..... 6

6 **2.2. SEX DIFFERENCES IN DEPRESSION-CARDIOVASCULAR DISEASE COMORBIDITY**.. 9

7 **3. THROUGH THE VAGUS NERVE: NON-INVASIVE NEUROMODULATION TECHNIQUES**

8 **AS ALTERNATIVE THERAPY** 11

9 **4. CONCLUSION** 14

10 **5. ACKNOWLEDGEMENTS** 15

11 **6. REFERENCES** 16

12

13

14 **1. INTRODUCTION**

15 The daily exposure to multiple psychosocial stress factors can result in a prolonged and frequent
16 activation of the stress response (McEwen, 2006). Furthermore, worry and rumination can extend
17 stress-related emotional and physiological activation, both in advance of and following stressors
18 (Brosschot et al., 2006). These situations represent significant pathophysiological risk factors and
19 lead to physical and psychological consequences. As a matter of fact, depression is the major stress-
20 related psychiatric disorder. The last official global health estimates reported that the total number of
21 people with depression exceed 300 million and the proportion of the world wide population with
22 depression is rated to be 4.4% (World Health Organization, 2017). When ranked by disability and
23 death combined, depression comes ninth behind killers such as stroke and HIV (Smith, 2014).

24 But what is the rationale behind this deadly fame? Darwin in 1872, commenting on the work of
25 Claude Bernard, emphasized the close bond between the brain and the heart: “*when the mind is*
26 *strongly excited, we might expect that it would instantly affect in a direct manner the heart; [...] when*
27 *the heart is affected it reacts on the brain; and the state of the brain again reacts through the pneumo-*
28 *gastric nerve on the heart; so that under any excitement there will be much mutual action and reaction*
29 *between these, the two most important organs of the body.*” (Darwin, 1990) So, through this intimate
30 connection, psychiatric disorders such as depression not only affect the brain but also involve the
31 heart. Countless evidence from the scientific literature has emphasized the link between
32 cardiovascular disease (CVD) and depression (Carney et al., 2003; Elderon & Whooley, 2013;
33 Freedland et al., 2003; Glassman, 2007; Lett et al., 2004; Penninx et al., 2001; Sgoifo et al., 2015;
34 Zellweger et al., 2004). Several studies, such as “The INTERHEART study”, examined modifiable
35 risk factors for acute myocardial infarction in over 25.000 patients from 52 different countries:
36 depression was officially recognized as a coronary heart disease (CHD) risk factor in the 2010 Global
37 Burden of Disease Study (Charlson et al., 2011; Nicholson et al. 2006; Yussuf et al., 2004).
38 Moreover, a wide number of authors reported that either major depressive disorder (MDD) or

39 significant depressive symptoms with substantial functional impairment are associated with an
40 increased risk of heart failure, stroke, peripheral artery disease and worse adverse outcomes (Grenon
41 et al., 2012; Pan et al., 2011; Rutledge & Linke 2007; Surtees et al., 2008). Depression has also been
42 shown to be an independent predictor of poor prognosis and re-hospitalization among patients with
43 established heart failure (Jiang et al., 2001) and patients with MDD are much more likely to suffer
44 acute cardiovascular sequelae such as myocardial infarction, congestive heart failure and
45 hypertension (Nemeroff & Goldschmidt-Clermont, 2012).

46 In the last years, multiple potential behavioural and biological factors have been identified as possible
47 substrates of this dangerous comorbidity. The effects of poor health behaviours have been extensively
48 highlighted in numerous papers (Brummett et al., 2003; Whooley et al., 2008; Win et al., 2011),
49 especially in The Heart and Soul Study (Sin et al., 2016), a prospective cohort study of 1024 subjects
50 with stable coronary heart disease: depressed patients had a 50% greater rate of adverse
51 cardiovascular events than those without depressive symptoms, but the difference was no longer
52 significant following adjustment for smoking, medication adherence and physical activity. Among
53 the pathophysiological pathways that could link depression and CVD, inflammatory processes,
54 enhanced activity of the hypothalamo-pituitary-adrenal (HPA) axis and alterations of the
55 cardiovascular autonomic control play a key role. Most of the evidence demonstrates that one-third
56 of patients with MDD shows elevated peripheral inflammatory biomarkers like c-reactive protein,
57 interleukin-6, interleukin-1 β and tumor necrosis factor- α (Baghai et al., 2018; Dowlati et al., 2010).
58 Moreover, a meta-analysis of 22 antidepressant treatment studies found that cytokine levels decreased
59 in response to therapy, along with a reduction in depressive symptoms (Hannestad et al., 2011). In
60 depression-related cardiovascular outcomes inflammation may act as a promotor for the progression
61 of atherosclerosis, inducing endothelial activation and expression of adhesion molecules and vascular
62 endothelial growth factors. The HPA axis hyperactivity may be reciprocally regulated by altered pro-
63 inflammatory pathways, constituting a complex bidirectional biological crosstalk (Baune et al.,

64 2012). This dysregulation may lead to increased vasoconstriction, heart rate and platelet activation,
65 factors that are directly implicated in the progression to CVD. However, among the possible
66 biological mediators that have been considered to explain the association between depression and
67 CVD, cardiovascular autonomic control dysfunction is the most investigated (Kemp et al., 2012).

68

69 2. CARDIAC AUTONOMIC CONTROL IN DEPRESSION

70 Heart rate variability (HRV) is a very useful non-invasive and sensitive indicator of autonomic
71 impairment. Lowered HRV is a widely recognized prognostic risk factor for adverse cardiovascular
72 events (e.g. myocardial infarction and arrhythmias) as well as cardiac mortality (Carney & Freedland,
73 2009; Thayer et al., 2010; van der Kooy et al., 2006). HRV analysis in the frequency domain identifies
74 two oscillatory components, namely low frequency (LF) and high frequency (HF), ranging from 0.04
75 to 0.15 Hz and from 0.15 to 0.4 Hz respectively. The HF band reflects parasympathetic activity and
76 its power is influenced by breathing whereas LF band seems to be produced by both sympathetic and
77 parasympathetic branches, even if its physiological interpretation is still controversial. Finally, the
78 ratio of LF to HF power (LF/HF) provides information about the sympatho-vagal balance (Shaffer &
79 Ginsberg JP, 2017). Alterations of autonomic nervous system that promote vagal withdrawal are
80 reflected in reductions of HRV. It is not surprising that a considerable body of research reports
81 reduced HRV and cardiac parasympathetic indexes, derived both in time and frequency domain
82 analysis, in patients with depression in comparison to healthy controls (Jangpangi et al., 2016; Koch
83 et al., 2019; Nahshoni et al., 2004; Sgoifo et al., 2015). In Kemp's meta-analysis, unmedicated
84 depressed patients displayed reduced HRV compared to control subjects in a standardized short-term
85 resting state condition (Kemp et al., 2012) and Shinba et al. observed that drug-naïve depressed
86 patients without comorbidity showed lower cardiac vagal tone and a shift of the sympathovagal
87 balance towards sympathetic prevalence when compared with healthy age-matched controls during
88 task execution (Shinba, 2017). Depression has been associated with decreased time domain measures

89 of HRV, including HF and several nonlinear measures, whereas the LF/HF ratio showed a significant
90 increase. Based on these data, we can imagine that the intrinsic mechanisms of regulation of HRV
91 are altered in this pathological condition, both at rest and in response to physiological and
92 psychosocial stimuli (Chen et al., 2017; Koch et al., 2019; Shinba, 2017). However, there is an
93 important bias in all these studies: sex differences were not carefully considered for the analysis.

94

95 **2.1. SEX DIFFERENCES IN THE RELATIONSHIP BETWEEN HRV AND** 96 **DEPRESSION**

97 As to sex differences, the first relevant element is the different prevalence of depression in women
98 versus men: women are about twice as likely to develop depression during their lifetime (Bromet et
99 al., 2011; Lucht et al., 2003, Seedat et al., 2009). In 2010, depression global annual prevalence was
100 5.5% and 3.2% for women and men respectively. Furthermore, women seem to manifest more
101 somatic symptoms of depression than men (Silverstein et al., 2013). The finding of similar prevalence
102 ratios in all developed countries suggests that the differential risk is indicative of a biologically based
103 sex difference. Studies on the short allele variant of the serotonin transporter-linked polymorphic
104 region (5-HTTLPR), which is associated with higher susceptibility to the development of depression
105 in response to environmental stress, identified this interaction more frequently in women than men
106 (Gressier et al., 2016; Sharpley et al., 2014; Uher & McGuffin, 2010). Specific forms of depression-
107 related disorders, e.g. premenstrual dysphoric disorder, postpartum depression and postmenopausal
108 depression, led to hypothesize the existence of a correlation between female hormonal fluctuations
109 and depression. Moreover, females and males seem to have similar rates of depression before puberty
110 and at ages older than 65 years (Bebbington et al., 2003; Burcusa & Iacono, 2007; Cyranowski et al.,
111 2000). From a large number of existing studies (Broderick & Korteland, 2002; Hampel & Petermann,
112 2005; Johnson & Whisman, 2014; Jose & Brown, 2008; Lopez et al., 2009; Peled & Moretti, 2007;
113 Tamres et al., 2002), higher propensity for ruminative thinking in women has been proposed as a

114 possible explanation for sex differences in prevalence rates of depression, as well (Nolen-Hoeksema,
115 2012).

116 Sex differences do not occur only in terms of prevalence of the disease but also in terms of disease
117 features. In particular, there are evidences about a sex effect on the relationship between depressive
118 symptoms and cardiac autonomic function. Depressed women are reported to have higher vagally
119 mediated cardiac control compared to depressed men (Chambers & Allen, 2007). Garcia et al.
120 evaluated cardiac autonomic control through passive tilt test in treatment-naive young adults with a
121 first episode of major depression and without any comorbid psychiatric disorder. They found that
122 young depressed males had significantly lower HRV during passive **orthostatic challenge** in
123 comparison to healthy age-matched control men, whereas there were no significant alterations in the
124 autonomic function of depressed women. They reported a more robust association of depressive
125 symptoms with poor cardiac vagal control and sympathetic predominance among depressed males
126 than females (Garcia et al., 2012). Similar results have been obtained by Chen et al.: mildly depressed
127 elderly men exhibited prominent sympathetic predominance compared to the control group, that
128 resulted mainly from diminished HF power and preserved LF power. In contrast, since both HF and
129 LF were attenuated among more depressed elderly males, sympathovagal balance showed no
130 differences in spite of profound vagal withdrawal. There were still no differences in HRV between
131 all depressed elderly female subgroups and the respective age-matched control group (Chen et al.,
132 2010). These results seem to imply a pervasive decline of cardiac autonomic function in depressed
133 men, but not in depressed women. Recent research studies have verified the existence of sex
134 differences in the association between depressive symptoms and cardiac autonomic dysfunction in a
135 non-clinical population, as well. Higher scores in daily depressive symptoms were associated with a
136 decreased circadian variation pattern of vagal activity in men but with increased circadian variation
137 pattern in the female group. In particular, a higher average amount of sadness experienced in daily
138 life was associated with higher levels of lnHF power in women (Jarczok et al., 2018a; Verkuil et al.

139 2015). A cross-lagged analysis over a 10-year period in the Whitehall II study revealed that higher
140 scores in vagal indexes at baseline are associated with a lower likelihood of depression incidence in
141 men but not in women (Jandackova et al., 2016). Further evidence also comes from animal models.
142 Within a population of 42 adult female *Macaca fascicularis* in a laboratory setting, Jarczok et al.
143 observed that females classified as behaviourally depressed showed higher vagal cardiac control
144 compared to non-depressed counterparts (Jarczok et al., 2018b).

145 A possible interpretation of sex differences in cardiac autonomic dysfunction of depressed patients
146 derives from the neurovisceral integration model (Thayer & Lane, 2009; **Figure 1**). A reduction of
147 grey matter volume in ventromedial prefrontal cortex (vmPFC) has been found in unmedicated male
148 patients with major depressive disorder, but not in the female counterpart (Yang et al., 2017). This
149 brain area exerts an inhibitory control over amygdala activity and stronger vmPFC-amygdala
150 connectivity predicts higher vagally mediated HRV (Sakaki et al., 2016). In addition, depressed
151 females but not depressed males were found to have a reduced amygdalar volume when compared
152 with sex-matched control subjects (Hastings et al., 2004).

153 Sex-related differences in HRV have generally been reported in the normal population (Koenig &
154 Thayer, 2016). Women show larger vagal modulation, despite they are characterized by a higher HR
155 relative to men. However, these differences seem to disappear with aging, especially from the age
156 group of 55–64 years (Voss et al., 2015). Furthermore, some authors demonstrated an increased HRV
157 in postmenopausal women with estrogens replacement therapy compared to women without hormone
158 therapy (Liu et al., 2003; Neves et al., 2007; Pikkujäämsä et al., 2001). Lastly, estrogens receptors
159 have been localized throughout the central autonomic network (McEwen et al., 2012). This evidence
160 suggests a possible role of estrogens in the female protective mechanism against the autonomic
161 alterations associated with depression. In addition, the vagal predominance observed in depressed
162 women could in part be due to the differential coping strategies that male and female subjects show
163 in response to chronic stressors (namely, fight-or-flight vs. tend-and-befriend response, respectively)

164 (Taylor et al., 2000). In fact, a greater oxytocin release in response to stress has been found in women
165 than in men (Taylor et al., 2000). Oxytocin-type neurons from the paraventricular nucleus synapse
166 on cardiovagal neurons in the nucleus of the solitary tract, the dorsal motor nucleus of the vagus, and
167 the nucleus ambiguus (Coote, 2013; Koenig and Thayer, 2016) and their excitation ultimately
168 determines an increase in vagal outflow. Moreover, the effects of oxytocin have been found to be
169 significantly enhanced by estrogens (Taylor et al., 2000).

170 All the above-mentioned evidence signals the need for additional studies to understand more about
171 sex differences in the cardiac autonomic control of depressed patients. This goal could provide new
172 insights into the etiopathogenesis of depression and promote the development of sex-specific
173 antidepressant therapies.

174

175 **2.2. SEX DIFFERENCES IN DEPRESSION-CARDIOVASCULAR DISEASE**

176 **COMORBIDITY**

177 The current state of art seems to highlight a great sex paradox in depression and cardiovascular disease
178 comorbidity. Although vagal activity is negatively associated with CVD risk and mortality in both
179 healthy and clinical subjects (Jarczok et al., 2018a; Thayer et al., 2010), depressive symptoms have
180 been associated with an increased risk of adverse cardiovascular events more in women than in men
181 (Bucciarelli et al., 2019; Möller-Leimkühler, 2007). Shah et al. found that depressive disorders predict
182 cardiovascular disease outcomes and increase risk of death in women aged ≤ 55 but not in
183 postmenopausal women and men (Shah et al., 2014). Furthermore, data from two cross-sectional
184 surveys (Community Mental Health Epidemiology Study and Third National Health and Nutrition
185 Examination Survey) revealed that young adult females with depression may be at excess risk of
186 premature cardiovascular-related death over a 15-year follow-up period (Shah et al., 2011; Wyman
187 et al., 2012). Possible pathophysiological mechanisms that could explain the highest incidence of
188 CVD in depressed women, despite the cardioprotective role of the vagus, are ascribed to: i)

189 inflammatory processes; ii) hormonal dysregulation; iii) poorer health behaviour; iv) metabolic
190 derangement (Bucciarelli et al., 2019; Webb et al., 2017). Several authors have highlighted a strong
191 connection between hormonal dysregulation and impaired inflammatory response in female
192 depressed patients. As a matter of fact, circulating estrogens stimulate the T- and B-lymphocytes,
193 with a greater immune and inflammatory response than men. Moreover, estrogens increases IL-1
194 secretion by macrophages and depressed women have increased eosinophil reactivity compared to
195 men, which may be explained by the presence of estrogens receptor alpha ($ER\alpha$) on their surface.
196 Elevated serum levels of IL-8, IFN- γ and leptin were found in the blood of depressed women when
197 compared to healthy controls and IL-6, TNF- α and IL-1 β levels are mainly elevated in the blood of
198 depressed women compared to depressed men, suggesting that these pro-inflammatory markers are
199 sex-specific in MDD patients. In general, estradiol appears to be linked to suppression of pro-
200 inflammatory cytokine production, such as reduced expression of IL-6 and TNF- α , and increased
201 production of anti-inflammatory cytokine IL-10 (Bucciarelli et al. 2019, Dudek et al. 2019, Webb et
202 al. 2017). However, further complicating this relationship is estradiol dose, as higher concentrations
203 are linked to anti-inflammatory responses, whereas low concentrations are associated with pro-
204 inflammatory responses (Mattina et al. 2019). Inflammation has been postulated to play a major role
205 in endothelial damage of the cerebral vasculature in depressed patients (Halaris 2016) and plays a
206 major role in the development of atherosclerosis and atherothrombosis. Thus, hormonal
207 dysregulation, through the activation of pro-inflammatory pathways, is supposed to be a risk factor
208 for the onset of CVD in depresses women. Finally, gonadal steroid receptors, such as $ER\alpha$ and $ER\beta$,
209 are expressed in the endothelial cell layer of the blood-brain barrier suggesting a further and direct
210 involvement of hormones in neurovascular alteration (Dudek et al. 2019).

211

212 3. THROUGH THE VAGUS NERVE: NON-INVASIVE NEUROMODULATION 213 TECHNIQUES AS ALTERNATIVE THERAPY

214 The link between cardiovascular autonomic control and MDD seems to be fundamental also in view
215 of new alternative therapies to drug treatment. Although pharmacological antidepressant treatment is
216 the gold standard therapy for major depression, up to 50–60% of patients do not obtain adequate
217 response following a first antidepressant drug treatment and about 40% of depressed patients do not
218 respond to 4 or more conventional treatments and are considered to have treatment-resistant
219 depression (Kemp et al., 2010; Otte et al., 2016; Rush et al., 2006). Moreover, pharmacological,
220 antidepressant treatment doesn't resolve reductions in HRV that have been observed in general
221 population despite decrease in depressive symptoms, suggesting that the pathology might have
222 residual effects on neurophysiological systems. In addition, several studies found that tricyclic
223 antidepressants significantly reduce HRV because of the anticholinergic and α 1-adrenergic properties
224 of this class of medication, while the effects on cardiovascular autonomic function of selective
225 serotonin reuptake inhibitors and serotonergic noradrenergic reuptake inhibitors are still debated
226 (Kemp et al., 2010; Koch et al., 2019). In view of such evidence, recent research studies have been
227 focused on trying to develop treatments that could be effective in non-responsive patients and have
228 cardioprotective effects (*Figure 2*). In their review, Iseger et al. proposed a frontal-vagal network that
229 overlaps with the functional areas affected by depression. As a matter of fact, several years of
230 neuroimaging research have shown that the depression-related decrease of metabolism and blood
231 flow in the prefrontal cortex and anterior cingulate and the pathologically increased activity in the
232 subgenual cingulate and amygdala are positively correlated with cardiovascular dysautonomic
233 features. These authors summarized the most promising neuromodulation techniques that target key
234 nodes for both depression and cardiac autonomic control (Iseger et al., 2019). For example, the
235 dorsolateral prefrontal cortex (DLPFC) has been frequently selected in the depression treatment as
236 the most suitable area for non-invasive neurostimulation such as repetitive Transcranial Magnetic

237 Stimulation (rTMS) and transcranial Direct Current Stimulation (tDCS). It has been hypothesized
238 that the antidepressant effect of DLPFC-stimulation is exerted via trans-synaptic modulation of the
239 subgenual cingulate cortex (sgACC). Lane et al. observed that depressed patients show an altered
240 emotional state shifting due to DLPFC hypoactivity and abnormal sgACC activity, which
241 subsequently leads to altered vagal control. These alterations are positively correlated with the
242 severity of depression and a concurrent increase in vagal indexes occurs when the pathological
243 condition is reversed by a successful treatment (Iseger et al., 2019; Lane et al., 2013). Surprisingly,
244 also the direct stimulation of the Vagus Nerve (VNS) has shown important antidepressant effects and
245 it was officially approved by The Food and Drug Administration in 2005 as an alternative therapy for
246 severely treatment-resistant depression. VNS has clear dose- and time-dependent effects on the brain
247 in key regions implicated in the neurobiology of depression such as prefrontal and cingulate cortex
248 (Carreno & Frazer, 2017; Kosel et al., 2011). An electrode is attached from a pacemaker implanted
249 on the left side of the chest to the left Vagus Nerve in the neck. It has been suggested that impulses
250 from the vagus nerve are transmitted to the following regions: locus coeruleus, raphe nuclei, and
251 nucleus tractus solitarius, which then project to other above-mentioned regions of the brain long
252 thought to be relevant for depression (Carreno & Frazer, 2017). To overcome the potential barriers
253 of applying VNS, which requires surgery, a non-invasive VNS method has been developed.
254 Transcutaneous Vagus Nerve Stimulation (tVNS) stimulates the afferent auricular branch of the
255 vagus nerve located on the surface of the ear and produces a similar effect to classical VNS in
256 reducing depressive symptoms. For instance, tVNS applied for 2 weeks in patients with depression,
257 once or twice for 15 minutes per day, significantly reduced depression scores (Hein et al., 2013). The
258 antidepressant effect as measured by the Beck Depression Inventory (BDI) was very prominent: it
259 showed subjective symptom amelioration in depressed patients of almost 50 % and the effects
260 appeared to be similar to other non-invasive brain stimulation techniques, such as rTMS (Fitzgerald
261 et al., 2006; Frank et al., 2011) and tDCS (Loo et al., 2010). Moreover, 4 weeks of tVNS was found
262 to modulate the resting state functional connectivity between the right amygdala and left DLPFC as

263 well as to enhance activation of the left insula and these changes were associated with improvement
264 in depressive symptomatology (Fang et al., 2016; Liu et al., 2016). The tVNS seems to be able to
265 alleviate depressive symptoms activating neuroprotective pathways and suppressing the
266 inflammation of the areas involved by pathology (Kong et al., 2018). The molecular process leading
267 to these results could be linked to the activation of $\alpha 7$ nicotinic acetylcholine receptors ($\alpha 7$ nAChRs),
268 expressed on neuronal cells, astrocytes and microglia cells (Pavlov & Tracey, 2005). The tVNS
269 determines an increased release of acetylcholine, massively activates these receptors and finally
270 implements a neuroprotective anti-inflammatory process in the compromised areas, through the
271 PI3K-Atk intracellular pathway, already observed in the inhibition of the peripheral macrophage
272 inflammatory response (Tyagi et al., 2010). Lastly, to the best of our knowledge, the influence of
273 tVNS on cardiovascular autonomic control in depressed patients has not yet been specifically studied.
274 However, in their study on 29 healthy volunteers aged ≥ 55 years, Bretherton et al. found that 2 weeks
275 of daily tVNS improve measures of vagal tone and some aspects of quality of life, mood and sleep,
276 which are all aspects affected by depression. Importantly, findings showed that improvements in
277 measures of autonomic balance were more pronounced in participants with greater baseline
278 sympathetic prevalence (Bretherton et al., 2019). In addition, tVNS performed on 48 healthy
279 participants significantly increased HRV, promoting a shift in cardiac autonomic function toward
280 parasympathetic predominance (Clancy et al., 2014). To fill this literature gap, further investigations
281 are needed to analyse the possible cardioprotective role of the tVNS in depressed patients.

282 All these non-invasive neuromodulation techniques modulate the entire frontal-vagal network rather
283 than just the local stimulation target. Thus, prolonged stimulation causes anatomical and functional
284 changes in the central nervous system and promotes the remodelling of damaged neuronal circuits.

285 Previous studies support gender-related differences in pharmacokinetics and pharmacodynamic
286 properties of antidepressant medications (LeGates et al. 2019) and men and women with chronic
287 depression show different responsivity to and tolerability of various antidepressant classes including

288 SSRIs, norepinephrinergic tetracyclic antidepressant and tricyclic antidepressant. However, only few
289 studies have assessed the gender differences in the antidepressant effect of new neuromodulation
290 techniques (D'Urso et al. 2017; Figiel et al. 1998; Conca et al. 2000; Brunoni et al. 2016) and authors
291 reported that gender was not a significant predictor in determining non-invasive neuromodulation
292 efficacy. Nevertheless, Kedzior and colleagues revealed in their meta-analysis, which included 54
293 sham-controlled trials between 1997 and 2013, that gender might be a positive predictor of response
294 as studies showing good antidepressant response to rTMS had mostly female patients (Kedzior et al.
295 2014). To the best of our knowledge, only one paper (Huang et al. 2008) highlighted a gender effect
296 in the therapeutic response to rTMS: while no difference was observed between male and
297 premenopausal female patients, 68.8% and 70.6% respectively, postmenopausal women did not
298 respond at all. They also found that greater improvement in depression score was associated with a
299 higher estradiol/progesterone ratio in premenopausal women, suggesting an important role of female
300 hormones in the therapeutic response.

301

302 4. CONCLUSION

303 Depression and cardiovascular disease currently represent two of the most common causes of
304 disability and mortality. Women seem to experience depressive disorders with a double incidence
305 than men. The latest studies have shown that depression in otherwise healthy subjects seems to
306 increase the risk of cardiovascular disease more strongly in young women, despite a higher vagally-
307 mediated heart rate variability. However, this sex paradox is still unresolved due to the lack of studies
308 in sex-balanced populations and randomized clinical studies including a larger number of women. To
309 the best of our knowledge the majority of research is correlational and does not longitudinally
310 examine the effects of depression on cardiac autonomic control and in particular on HRV. Moreover,
311 most studies present mixed gender groups and only a few of them considers gender differences in the
312 analysis of results. Finally, it is difficult to analyse any adaptations related to the disease alone since

313 antidepressants have a great impact on the cardiovascular autonomic control. Further longitudinal
314 studies are required assess the adaptation of the cardiovascular autonomic control in depressed
315 patients and on the potential sex differences. Therefore, sex differences should be more carefully
316 considered as they can add new insights into the etiopathogenesis of both these pathologies and lead
317 to more effective therapeutic approaches. For instance, the frontal-vagal network proposed by Iseger
318 et al. best highlights the target areas of new neuromodulatory therapies for depression, emphasizing
319 the importance of the bidirectionality of heart-brain axis and the direct or indirect involvement of the
320 vagus. Based on this, it is even more important to consider HRV measures in depression studies as a
321 prognostic factor and in order to assess the influence of neuromodulation on cardiovascular
322 autonomic control. New studies are required to shed further light on the effects of these new
323 antidepressant therapies in relation to sex differences both from the point of view of efficacy and in
324 the evaluation of sex-related differences in the neuromodulation of the areas involved by depression.

325

326 5. ACKNOWLEDGEMENTS

327 This work was supported by the Italian Ministry of Health (RC-2019 to Prof. Nicola Montano).

328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352

6. REFERENCES

1. Baghai, T.C., Varallo-Bedarida, G., Born, C., Häfner, S., Schüle, C., Eser, D., Zill, P., Manook, A., Weigl, J., Jooyandeh, S., Nothdurfter, C., von Schacky, C., Bondy, B., Rupprecht, R., 2018. Classical Risk Factors and Inflammatory Biomarkers: One of the Missing Biological Links between Cardiovascular Disease and Major Depressive Disorder. *Int J Mol Sci* 19. <https://doi.org/10.3390/ijms19061740>
2. Baune, B.T., Stuart, M., Gilmour, A., Wersching, H., Heindel, W., Arolt, V., Berger, K., 2012. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. *Transl Psychiatry* 2, e92. <https://doi.org/10.1038/tp.2012.18>
3. Bebbington, P., Dunn, G., Jenkins, R., Lewis, G., Brugha, T., Farrell, M., Meltzer, H., 2003. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. *Int Rev Psychiatry* 15, 74–83. <https://doi.org/10.1080/0954026021000045976>
4. Bretherton, B., Atkinson, L., Murray, A., Clancy, J., Deuchars, S., Deuchars, J., 2019. Effects of transcutaneous vagus nerve stimulation in individuals aged 55 years or above: potential benefits of daily stimulation. *Aging (Albany NY)* 11, 4836–4857. <https://doi.org/10.18632/aging.102074>
5. Broderick, P.C., Korteland, C., 2002. Coping Style and Depression in Early Adolescence: Relationships to Gender, Gender Role, and Implicit Beliefs. *Sex Roles* 46, 201–213. <https://doi.org/10.1023/A:1019946714220>
6. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., Karam, A.N., Kaur, J., Kostyuchenko, S., Lépine, J.-P., Levinson, D., Matschinger, H., Mora, M.E.M., Browne, M.O., Posada-Villa, J., Viana,

- 353 M.C., Williams, D.R., Kessler, R.C., 2011. Cross-national epidemiology of DSM-IV major
354 depressive episode. *BMC Med* 9, 90. <https://doi.org/10.1186/1741-7015-9-90>
- 355 7. Brosschot, J.F., Gerin, W., Thayer, J.F., 2006. The perseverative cognition hypothesis: a
356 review of worry, prolonged stress-related physiological activation, and health. *J Psychosom*
357 *Res* 60, 113–124. <https://doi.org/10.1016/j.jpsychores.2005.06.074>
- 358 8. Brummett, B.H., Babyak, M.A., Siegler, I.C., Mark, D.B., Williams, R.B., Barefoot, J.C.,
359 2003. Effect of smoking and sedentary behavior on the association between depressive
360 symptoms and mortality from coronary heart disease. *Am. J. Cardiol.* 92, 529–532.
361 [https://doi.org/10.1016/s0002-9149\(03\)00719-7](https://doi.org/10.1016/s0002-9149(03)00719-7)
- 362 9. Brunoni, A.R., Moffa, A.H., Fregni, F., Palm, U., Padberg, F., Blumberger, D.M.,
363 Daskalakis, Z.J., Bennabi, D., Haffen, E., Alonzo, A., Loo, C.K., 2016. Transcranial direct
364 current stimulation for acute major depressive episodes: meta-analysis of individual patient
365 data. *Br J Psychiatry* 208, 522–531. <https://doi.org/10.1192/bjp.bp.115.164715>
- 366 10. Bucciarelli, V., Caterino, A.L., Bianco, F., Caputi, C.G., Salerno, S., Sciomer, S., Maffei, S.,
367 Gallina, S., 2019. Depression and cardiovascular disease: The deep blue sea of women’s
368 heart. *Trends Cardiovasc. Med.* <https://doi.org/10.1016/j.tcm.2019.05.001>
- 369 11. Burcusa, S.L., Iacono, W.G., 2007. Risk for recurrence in depression. *Clin Psychol Rev* 27,
370 959–985. <https://doi.org/10.1016/j.cpr.2007.02.005>
- 371 12. Carney, R.M., Blumenthal, J.A., Catellier, D., Freedland, K.E., Berkman, L.F., Watkins,
372 L.L., Czajkowski, S.M., Hayano, J., Jaffe, A.S., 2003. Depression as a risk factor for
373 mortality after acute myocardial infarction. *Am. J. Cardiol.* 92, 1277–1281.
374 <https://doi.org/10.1016/j.amjcard.2003.08.007>
- 375 13. Carney, R.M., Freedland, K.E., 2009. Depression and heart rate variability in patients with
376 coronary heart disease. *Cleve Clin J Med* 76 Suppl 2, S13-17.
377 <https://doi.org/10.3949/ccjm.76.s2.03>

- 378 14. Carreno, F.R., Frazer, A., 2017. Vagal Nerve Stimulation for Treatment-Resistant
379 Depression. *Neurotherapeutics* 14, 716–727. <https://doi.org/10.1007/s13311-017-0537-8>
- 380 15. Chambers, A.S., Allen, J.J.B., 2007. Sex differences in cardiac vagal control in a depressed
381 sample: implications for differential cardiovascular mortality. *Biol Psychol* 75, 32–36.
382 <https://doi.org/10.1016/j.biopsycho.2006.11.001>
- 383 16. Charlson, F.J., Stapelberg, N.J.C., Baxter, A.J., Whiteford, H.A., 2011. Should global burden
384 of disease estimates include depression as a risk factor for coronary heart disease? *BMC Med*
385 9, 47. <https://doi.org/10.1186/1741-7015-9-47>
- 386 17. Chen, H.-C., Yang, C.C.H., Kuo, T.B.J., Su, T.-P., Chou, P., 2010. Gender differences in the
387 relationship between depression and cardiac autonomic function among community elderly.
388 *Int J Geriatr Psychiatry* 25, 314–322. <https://doi.org/10.1002/gps.2341>
- 389 18. Chen, X., Yang, R., Kuang, D., Zhang, L., Lv, R., Huang, X., Wu, F., Lao, G., Ou, S., 2017.
390 Heart rate variability in patients with major depression disorder during a clinical autonomic
391 test. *Psychiatry Res* 256, 207–211. <https://doi.org/10.1016/j.psychres.2017.06.041>
- 392 19. Clancy, J.A., Mary, D.A., Witte, K.K., Greenwood, J.P., Deuchars, S.A., Deuchars, J., 2014.
393 Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity.
394 *Brain Stimul* 7, 871–877. <https://doi.org/10.1016/j.brs.2014.07.031>
- 395 20. Conca, A., Swoboda, E., König, P., Koppi, S., Beraus, W., Künz, A., Fritzsche, H., Weiss,
396 P., 2000. Clinical impacts of single transcranial magnetic stimulation (sTMS) as an add-on
397 therapy in severely depressed patients under SSRI treatment. *Hum Psychopharmacol* 15,
398 429–438. [https://doi.org/10.1002/1099-1077\(200008\)15:6<429::AID-HUP227>3.0.CO;2-3](https://doi.org/10.1002/1099-1077(200008)15:6<429::AID-HUP227>3.0.CO;2-3)
- 399 21. Coote, J.H., 2013. Myths and realities of the cardiac vagus. *J. Physiol. (Lond.)* 591, 4073–
400 4085. <https://doi.org/10.1113/jphysiol.2013.257758>
- 401 22. Cyranowski, J.M., Frank, E., Young, E., Shear, M.K., 2000. Adolescent onset of the gender
402 difference in lifetime rates of major depression: a theoretical model. *Arch. Gen. Psychiatry*
403 57, 21–27. <https://doi.org/10.1001/archpsyc.57.1.21>

- 404 23. D'Urso, G., Dell'Osso, B., Rossi, R., Brunoni, A.R., Bortolomasi, M., Ferrucci, R., Priori,
405 A., de Bartolomeis, A., Altamura, A.C., 2017. Clinical predictors of acute response to
406 transcranial direct current stimulation (tDCS) in major depression. *J Affect Disord* 219, 25–
407 30. <https://doi.org/10.1016/j.jad.2017.05.019>
- 408 24. Darwin, C., 1990. *The Works of Charles Darwin, Volume 23: The Expression of the*
409 *Emotions in Man and Animals*. NYU Press.
- 410 25. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L.,
411 2010. A meta-analysis of cytokines in major depression. *Biol. Psychiatry* 67, 446–457.
412 <https://doi.org/10.1016/j.biopsych.2009.09.033>
- 413 26. Dudek, K.A., Dion-Albert, L., Kaufmann, F.N., Tuck, E., Lebel, M., Menard, C., n.d.
414 Neurobiology of resilience in depression: immune and vascular insights from human and
415 animal studies. *European Journal of Neuroscience* n/a. <https://doi.org/10.1111/ejn.14547>
- 416 27. Elderon, L., Whooley, M.A., 2013. Depression and cardiovascular disease. *Prog Cardiovasc*
417 *Dis* 55, 511–523. <https://doi.org/10.1016/j.pcad.2013.03.010>
- 418 28. Fang, J., Egorova, N., Rong, P., Liu, J., Hong, Y., Fan, Y., Wang, X., Wang, H., Yu, Y., Ma,
419 Y., Xu, C., Li, S., Zhao, J., Luo, M., Zhu, B., Kong, J., 2017. Early cortical biomarkers of
420 longitudinal transcutaneous vagus nerve stimulation treatment success in depression.
421 *Neuroimage Clin* 14, 105–111. <https://doi.org/10.1016/j.nicl.2016.12.016>
- 422 29. Figiel, G.S., Epstein, C., McDonald, W.M., Amazon-Leece, J., Figiel, L., Saldivia, A.,
423 Glover, S., 1998. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory
424 depressed patients. *J Neuropsychiatry Clin Neurosci* 10, 20–25.
425 <https://doi.org/10.1176/jnp.10.1.20>
- 426 30. Fitzgerald, P.B., Benitez, J., de Castella, A., Daskalakis, Z.J., Brown, T.L., Kulkarni, J., 2006.
427 A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic
428 stimulation for treatment-resistant depression. *Am J Psychiatry* 163, 88–94.
429 <https://doi.org/10.1176/appi.ajp.163.1.88>

- 430 31. Frank, E., Eichhammer, P., Burger, J., Zowe, M., Landgrebe, M., Hajak, G., Langguth, B.,
431 2011. Transcranial magnetic stimulation for the treatment of depression: feasibility and
432 results under naturalistic conditions: a retrospective analysis. *Eur Arch Psychiatry Clin*
433 *Neurosci* 261, 261–266. <https://doi.org/10.1007/s00406-010-0137-7>
- 434 32. Freedland, K.E., Rich, M.W., Skala, J.A., Carney, R.M., Dávila-Román, V.G., Jaffe, A.S.,
435 2003. Prevalence of depression in hospitalized patients with congestive heart failure.
436 *Psychosom Med* 65, 119–128. <https://doi.org/10.1097/01.psy.0000038938.67401.85>
- 437 33. Garcia, R.G., Zarruk, J.G., Guzman, J.C., Barrera, C., Pinzon, A., Trillos, E., Lopez-
438 Jaramillo, P., Morillo, C.A., Maior, R.S., Diaz-Quijano, F.A., Tomaz, C., 2012. Sex
439 differences in cardiac autonomic function of depressed young adults. *Biol Psychol* 90, 179–
440 185. <https://doi.org/10.1016/j.biopsycho.2012.03.016>
- 441 34. Glassman, A.H., 2007. Depression and cardiovascular comorbidity. *Dialogues Clin Neurosci*
442 9, 9–17.
- 443 35. Grenon, S.M., Hiramoto, J., Smolderen, K.G., Vittinghoff, E., Whooley, M.A., Cohen, B.E.,
444 2012. Association between depression and peripheral artery disease: insights from the heart
445 and soul study. *J Am Heart Assoc* 1, e002667. <https://doi.org/10.1161/JAHA.112.002667>
- 446 36. Gressier, F., Calati, R., Serretti, A., 2016. 5-HTTLPR and gender differences in affective
447 disorders: A systematic review. *J Affect Disord* 190, 193–207.
448 <https://doi.org/10.1016/j.jad.2015.09.027>
- 449 37. Halaris, A., Leonard, B.E., 2013. *Inflammation in Psychiatry*. Karger Medical and Scientific
450 Publishers.
- 451 38. Hampel, P., Petermann, F., 2005. Age and Gender Effects on Coping in Children and
452 Adolescents. *J Youth Adolescence* 34, 73–83. <https://doi.org/10.1007/s10964-005-3207-9>
- 453 39. Hannestad, J., DellaGioia, N., Bloch, M., 2011. The effect of antidepressant medication
454 treatment on serum levels of inflammatory cytokines: a meta-analysis.
455 *Neuropsychopharmacology* 36, 2452–2459. <https://doi.org/10.1038/npp.2011.132>

- 456 40. Hastings, R.S., Parsey, R.V., Oquendo, M.A., Arango, V., Mann, J.J., 2004. Volumetric
457 analysis of the prefrontal cortex, amygdala, and hippocampus in major depression.
458 *Neuropsychopharmacology* 29, 952–959. <https://doi.org/10.1038/sj.npp.1300371>
- 459 41. Hein, E., Nowak, M., Kiess, O., Biermann, T., Bayerlein, K., Kornhuber, J., Kraus, T., 2013.
460 Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized
461 controlled pilot study. *J Neural Transm (Vienna)* 120, 821–827.
462 <https://doi.org/10.1007/s00702-012-0908-6>
- 463 42. Huang, C.-C., Wei, I.-H., Chou, Y.-H., Su, T.-P., 2008. Effect of age, gender, menopausal
464 status, and ovarian hormonal level on rTMS in treatment-resistant depression.
465 *Psychoneuroendocrinology* 33, 821–831. <https://doi.org/10.1016/j.psyneuen.2008.03.006>
- 466 43. Iseger, T.A., van Bueren, N.E.R., Kenemans, J.L., Gevirtz, R., Arns, M., 2019. A frontal-
467 vagal network theory for Major Depressive Disorder: Implications for optimizing
468 neuromodulation techniques. *Brain Stimulation*. <https://doi.org/10.1016/j.brs.2019.10.006>
- 469 44. Jandackova, V.K., Britton, A., Malik, M., Steptoe, A., 2016. Heart rate variability and
470 depressive symptoms: a cross-lagged analysis over a 10-year period in the Whitehall II study.
471 *Psychol Med* 46, 2121–2131. <https://doi.org/10.1017/S003329171600060X>
- 472 45. Jangpangi, D., Mondal, S., Bandhu, R., Kataria, D., Gandhi, A., 2016. Alteration of Heart
473 Rate Variability in Patients of Depression. *J Clin Diagn Res* 10, CM04–CM06.
474 <https://doi.org/10.7860/JCDR/2016/22882.9063>
- 475 46. Jarczok, M.N., Aguilar-Raab, C., Koenig, J., Kaess, M., Borniger, J.C., Nelson, R.J., Hall,
476 M., Ditzen, B., Thayer, J.F., Fischer, J.E., 2018a. The Heart’s rhythm “n” blues: Sex
477 differences in circadian variation patterns of vagal activity vary by depressive symptoms in
478 predominantly healthy employees. *Chronobiol. Int.* 35, 896–909.
479 <https://doi.org/10.1080/07420528.2018.1439499>
- 480 47. Jarczok, M.N., Koenig, J., Shively, C.A., Thayer, J.F., 2018b. Behavioral depression is
481 associated with increased vagally mediated heart rate variability in adult female cynomolgus

- 482 monkeys (*Macaca fascicularis*). *Int J Psychophysiol* 131, 139–143.
483 <https://doi.org/10.1016/j.ijpsycho.2017.11.004>
- 484 48. Jiang, W., Alexander, J., Christopher, E., Kuchibhatla, M., Gaulden, L.H., Cuffe, M.S.,
485 Blazing, M.A., Davenport, C., Califf, R.M., Krishnan, R.R., O'Connor, C.M., 2001.
486 Relationship of depression to increased risk of mortality and rehospitalization in patients with
487 congestive heart failure. *Arch. Intern. Med.* 161, 1849–1856.
488 <https://doi.org/10.1001/archinte.161.15.1849>
- 489 49. Johnson, D.P., Whisman, M.A., 2013. Gender differences in rumination: A meta-analysis.
490 *Pers Individ Dif* 55, 367–374. <https://doi.org/10.1016/j.paid.2013.03.019>
- 491 50. Jose, P.E., Brown, I., 2008. When does the gender difference in rumination begin? Gender
492 and age differences in the use of rumination by adolescents. *Journal of Youth and*
493 *Adolescence* 37, 180–192. <https://doi.org/10.1007/s10964-006-9166-y>
- 494 51. Kedzior, K.K., Azorina, V., Reitz, S.K., 2014. More female patients and fewer stimuli per
495 session are associated with the short-term antidepressant properties of repetitive transcranial
496 magnetic stimulation (rTMS): a meta-analysis of 54 sham-controlled studies published
497 between 1997–2013. *Neuropsychiatr Dis Treat* 10, 727–756.
498 <https://doi.org/10.2147/NDT.S58405>
- 499 52. Kemp, A.H., Quintana, D.S., Felmingham, K.L., Matthews, S., Jelinek, H.F., 2012.
500 Depression, comorbid anxiety disorders, and heart rate variability in physically healthy,
501 unmedicated patients: implications for cardiovascular risk. *PLoS ONE* 7, e30777.
502 <https://doi.org/10.1371/journal.pone.0030777>
- 503 53. Kemp, A.H., Quintana, D.S., Gray, M.A., Felmingham, K.L., Brown, K., Gatt, J.M., 2010.
504 Impact of depression and antidepressant treatment on heart rate variability: a review and
505 meta-analysis. *Biol. Psychiatry* 67, 1067–1074.
506 <https://doi.org/10.1016/j.biopsycho.2009.12.012>

- 507 54. Koch, C., Wilhelm, M., Salzman, S., Rief, W., Euteneuer, F., 2019. A meta-analysis of heart
508 rate variability in major depression. *Psychol Med* 49, 1948–1957.
509 <https://doi.org/10.1017/S0033291719001351>
- 510 55. Koenig, J., Thayer, J.F., 2016. Sex differences in healthy human heart rate variability: A
511 meta-analysis. *Neurosci Biobehav Rev* 64, 288–310.
512 <https://doi.org/10.1016/j.neubiorev.2016.03.007>
- 513 56. Kong, J., Fang, J., Park, J., Li, S., Rong, P., 2018. Treating Depression with Transcutaneous
514 Auricular Vagus Nerve Stimulation: State of the Art and Future Perspectives. *Front*
515 *Psychiatry* 9, 20. <https://doi.org/10.3389/fpsyt.2018.00020>
- 516 57. Kosel, M., Brockmann, H., Frick, C., Zobel, A., Schlaepfer, T.E., 2011. Chronic vagus nerve
517 stimulation for treatment-resistant depression increases regional cerebral blood flow in the
518 dorsolateral prefrontal cortex. *Psychiatry Res* 191, 153–159.
519 <https://doi.org/10.1016/j.psychresns.2010.11.004>
- 520 58. Lane, R.D., Weidenbacher, H., Smith, R., Fort, C., Thayer, J.F., Allen, J.J.B., 2013.
521 Subgenual anterior cingulate cortex activity covariation with cardiac vagal control is altered
522 in depression. *J Affect Disord* 150, 565–570. <https://doi.org/10.1016/j.jad.2013.02.005>
- 523 59. LeGates, T.A., Kvarta, M.D., Thompson, S.M., 2019. Sex differences in antidepressant
524 efficacy. *Neuropsychopharmacology* 44, 140–154. [https://doi.org/10.1038/s41386-018-](https://doi.org/10.1038/s41386-018-0156-z)
525 [0156-z](https://doi.org/10.1038/s41386-018-0156-z)
- 526 60. Lett, H.S., Blumenthal, J.A., Babyak, M.A., Sherwood, A., Strauman, T., Robins, C.,
527 Newman, M.F., 2004. Depression as a risk factor for coronary artery disease: evidence,
528 mechanisms, and treatment. *Psychosom Med* 66, 305–315.
529 <https://doi.org/10.1097/01.psy.0000126207.43307.c0>
- 530 61. Liu, C.C., Kuo, T.B.J., Yang, C.C.H., 2003. Effects of estrogen on gender-related autonomic
531 differences in humans. *Am. J. Physiol. Heart Circ. Physiol.* 285, H2188-2193.
532 <https://doi.org/10.1152/ajpheart.00256.2003>

- 533 62. Liu, J., Fang, J., Wang, Z., Rong, P., Hong, Y., Fan, Y., Wang, X., Park, J., Jin, Y., Liu, C.,
534 Zhu, B., Kong, J., 2016. Transcutaneous vagus nerve stimulation modulates amygdala
535 functional connectivity in patients with depression. *J Affect Disord* 205, 319–326.
536 <https://doi.org/10.1016/j.jad.2016.08.003>
- 537 63. Loo, C.K., Sachdev, P., Martin, D., Pigot, M., Alonzo, A., Malhi, G.S., Lagopoulos, J.,
538 Mitchell, P., 2010. A double-blind, sham-controlled trial of transcranial direct current
539 stimulation for the treatment of depression. *Int. J. Neuropsychopharmacol.* 13, 61–69.
540 <https://doi.org/10.1017/S1461145709990411>
- 541 64. Lopez, C.M., Driscoll, K.A., Kistner, J.A., 2009. Sex differences and response styles:
542 subtypes of rumination and associations with depressive symptoms. *J Clin Child Adolesc*
543 *Psychol* 38, 27–35. <https://doi.org/10.1080/15374410802575412>
- 544 65. Lucht, M., Schaub, R.T., Meyer, C., Hapke, U., Rumpf, H.J., Bartels, T., von Houwald, J.,
545 Barnow, S., Freyberger, H.J., Dilling, H., John, U., 2003. Gender differences in unipolar
546 depression: a general population survey of adults between age 18 to 64 of German nationality.
547 *J Affect Disord* 77, 203–211. [https://doi.org/10.1016/s0165-0327\(02\)00121-0](https://doi.org/10.1016/s0165-0327(02)00121-0)
- 548 66. Mattina, G.F., Van Lieshout, R.J., Steiner, M., 2019. Inflammation, depression and
549 cardiovascular disease in women: the role of the immune system across critical reproductive
550 events. *Ther Adv Cardiovasc Dis* 13. <https://doi.org/10.1177/1753944719851950>
- 551 67. McEwen, B.S., 2006. Protective and damaging effects of stress mediators: central role of the
552 brain. *Dialogues Clin Neurosci* 8, 367–381.
- 553 68. McEwen, B.S., Akama, K.T., Spencer-Segal, J.L., Milner, T.A., Waters, E.M., 2012.
554 Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms.
555 *Behav. Neurosci.* 126, 4–16. <https://doi.org/10.1037/a0026708>
- 556 69. Möller-Leimkühler, A.M., 2007. Gender differences in cardiovascular disease and comorbid
557 depression. *Dialogues Clin Neurosci* 9, 71–83.

- 558 70. Nahshoni, E., Aravot, D., Aizenberg, D., Sigler, M., Zalsman, G., Strasberg, B., Imbar, S.,
559 Adler, E., Weizman, A., 2004. Heart rate variability in patients with major depression.
560 *Psychosomatics* 45, 129–134. <https://doi.org/10.1176/appi.psy.45.2.129>
- 561 71. Nemeroff, C.B., Goldschmidt-Clermont, P.J., 2012. Heartache and heartbreak--the link
562 between depression and cardiovascular disease. *Nat Rev Cardiol* 9, 526–539.
563 <https://doi.org/10.1038/nrcardio.2012.91>
- 564 72. Neves, V.F.C., Silva de Sá, M.F., Gallo, L., Catai, A.M., Martins, L.E.B., Crescêncio, J.C.,
565 Perpétuo, N.M., Silva, E., 2007. Autonomic modulation of heart rate of young and
566 postmenopausal women undergoing estrogen therapy. *Braz. J. Med. Biol. Res.* 40, 491–499.
567 <https://doi.org/10.1590/s0100-879x2007000400007>
- 568 73. Nicholson, A., Kuper, H., Hemingway, H., 2006. Depression as an aetiologic and prognostic
569 factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants
570 in 54 observational studies. *Eur. Heart J.* 27, 2763–2774.
571 <https://doi.org/10.1093/eurheartj/ehl338>
- 572 74. Nolen-Hoeksema, S., 2012. Emotion regulation and psychopathology: the role of gender.
573 *Annu Rev Clin Psychol* 8, 161–187. <https://doi.org/10.1146/annurev-clinpsy-032511-143109>
- 574
- 575 75. Otte, C., Gold, S.M., Penninx, B.W., Pariante, C.M., Etkin, A., Fava, M., Mohr, D.C.,
576 Schatzberg, A.F., 2016. Major depressive disorder. *Nat Rev Dis Primers* 2, 16065.
577 <https://doi.org/10.1038/nrdp.2016.65>
- 578 76. Pan, A., Sun, Q., Okereke, O.I., Rexrode, K.M., Hu, F.B., 2011. Depression and risk of stroke
579 morbidity and mortality: a meta-analysis and systematic review. *JAMA* 306, 1241–1249.
580 <https://doi.org/10.1001/jama.2011.1282>
- 581 77. Pavlov, V.A., Tracey, K.J., 2005. The cholinergic anti-inflammatory pathway. *Brain Behav.*
582 *Immun.* 19, 493–499. <https://doi.org/10.1016/j.bbi.2005.03.015>

- 583 78. Peled, M., Moretti, M.M., 2007. Rumination on anger and sadness in adolescence: fueling of
584 fury and deepening of despair. *Journal of clinical child and adolescent psychology: the*
585 *official journal for the Society of Clinical Child and Adolescent Psychology*, American
586 Psychological Association, Division 53 36, 66–75.
587 <https://doi.org/10.1080/15374410709336569>
- 588 79. Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T., van
589 Tilburg, W., 2001. Depression and cardiac mortality: results from a community-based
590 longitudinal study. *Arch. Gen. Psychiatry* 58, 221–227.
591 <https://doi.org/10.1001/archpsyc.58.3.221>
- 592 80. Pikkujämsä, S.M., Mäkikallio, T.H., Airaksinen, K.E., Huikuri, H.V., 2001. Determinants
593 and interindividual variation of R-R interval dynamics in healthy middle-aged subjects. *Am.*
594 *J. Physiol. Heart Circ. Physiol.* 280, H1400-1406.
595 <https://doi.org/10.1152/ajpheart.2001.280.3.H1400>
- 596 81. Rush, A.J., Kraemer, H.C., Sackeim, H.A., Fava, M., Trivedi, M.H., Frank, E., Ninan, P.T.,
597 Thase, M.E., Gelenberg, A.J., Kupfer, D.J., Regier, D.A., Rosenbaum, J.F., Ray, O.,
598 Schatzberg, A.F., ACNP Task Force, 2006. Report by the ACNP Task Force on response and
599 remission in major depressive disorder. *Neuropsychopharmacology* 31, 1841–1853.
600 <https://doi.org/10.1038/sj.npp.1301131>
- 601 82. Rutledge, T., Linke, S.E., 2007. Phobic anxiety and depression increase the risk of ventricular
602 arrhythmias in people with coronary artery disease. *Evid Based Ment Health* 10, 43.
603 <https://doi.org/10.1136/ebmh.10.2.43>
- 604 83. Sakaki, M., Yoo, H.J., Nga, L., Lee, T.-H., Thayer, J.F., Mather, M., 2016. Heart rate
605 variability is associated with amygdala functional connectivity with MPFC across younger
606 and older adults. *Neuroimage* 139, 44–52. <https://doi.org/10.1016/j.neuroimage.2016.05.076>
- 607 84. Seedat, S., Scott, K.M., Angermeyer, M.C., Berglund, P., Bromet, E.J., Brugha, T.S.,
608 Demyttenaere, K., de Girolamo, G., Haro, J.M., Jin, R., Karam, E.G., Kovess-Masfety, V.,


- 609 Levinson, D., Medina Mora, M.E., Ono, Y., Ormel, J., Pennell, B.-E., Posada-Villa, J.,
610 Sampson, N.A., Williams, D., Kessler, R.C., 2009. Cross-national associations between
611 gender and mental disorders in the World Health Organization World Mental Health Surveys.
612 *Arch. Gen. Psychiatry* 66, 785–795. <https://doi.org/10.1001/archgenpsychiatry.2009.36>
- 613 85. Sgoifo, A., Carnevali, L., Alfonso, M. de los A.P., Amore, M., 2015. Autonomic dysfunction
614 and heart rate variability in depression. *Stress* 18, 343–352.
615 <https://doi.org/10.3109/10253890.2015.1045868>
- 616 86. Shaffer, F., Ginsberg, J.P., 2017. An Overview of Heart Rate Variability Metrics and Norms.
617 *Front Public Health* 5. <https://doi.org/10.3389/fpubh.2017.00258>
- 618 87. Shah, A.J., Ghasemzadeh, N., Zaragoza-Macias, E., Patel, R., Eapen, D.J., Neeland, I.J.,
619 Pimple, P.M., Zafari, A.M., Quyyumi, A.A., Vaccarino, V., 2014. Sex and age differences in
620 the association of depression with obstructive coronary artery disease and adverse
621 cardiovascular events. *J Am Heart Assoc* 3, e000741.
622 <https://doi.org/10.1161/JAHA.113.000741>
- 623 88. Shah, A.J., Ghasemzadeh, N., Zaragoza-Macias, E., Patel, R., Eapen, D.J., Neeland, I.J.,
624 Pimple, P.M., Zafari, A.M., Quyyumi, A.A., Vaccarino, V., 2014. Sex and Age Differences
625 in the Association of Depression With Obstructive Coronary Artery Disease and Adverse
626 Cardiovascular Events. *J Am Heart Assoc* 3. <https://doi.org/10.1161/JAHA.113.000741>
- 627 89. Shah, A.J., Veledar, E., Hong, Y., Bremner, J.D., Vaccarino, V., 2011. Depression and
628 history of attempted suicide as risk factors for heart disease mortality in young individuals.
629 *Arch. Gen. Psychiatry* 68, 1135–1142. <https://doi.org/10.1001/archgenpsychiatry.2011.125>
- 630 90. Sharpley, C.F., Palanisamy, S.K.A., Glyde, N.S., Dillingham, P.W., Agnew, L.L., 2014. An
631 update on the interaction between the serotonin transporter promoter variant (5-HTTLPR),
632 stress and depression, plus an exploration of non-confirming findings. *Behav. Brain Res.* 273,
633 89–105. <https://doi.org/10.1016/j.bbr.2014.07.030>

- 634 91. Shinba, T., 2017. Major depressive disorder and generalized anxiety disorder show different
635 autonomic dysregulations revealed by heart-rate variability analysis in first-onset drug-naïve
636 patients without comorbidity. *Psychiatry Clin. Neurosci.* 71, 135–145.
637 <https://doi.org/10.1111/pcn.12494>
- 638 92. Silverstein, B., Edwards, T., Gamma, A., Ajdacic-Gross, V., Rossler, W., Angst, J., 2013.
639 The role played by depression associated with somatic symptomatology in accounting for the
640 gender difference in the prevalence of depression. *Soc Psychiatry Psychiatr Epidemiol* 48,
641 257–263. <https://doi.org/10.1007/s00127-012-0540-7>
- 642 93. Sin, N.L., Kumar, A.D., Gehi, A.K., Whooley, M.A., 2016. Direction of Association Between
643 Depressive Symptoms and Lifestyle Behaviors in Patients with Coronary Heart Disease: the
644 Heart and Soul Study. *Ann Behav Med* 50, 523–532. [https://doi.org/10.1007/s12160-016-](https://doi.org/10.1007/s12160-016-9777-9)
645 [9777-9](https://doi.org/10.1007/s12160-016-9777-9)
- 646 94. Smith, K., 2014. Mental health: a world of depression. *Nature* 515, 181.
647 <https://doi.org/10.1038/515180a>
- 648 95. Surtees, P.G., Wainwright, N.W.J., Luben, R.N., Wareham, N.J., Bingham, S.A., Khaw, K.-
649 T., 2008. Psychological distress, major depressive disorder, and risk of stroke. *Neurology* 70,
650 788–794. <https://doi.org/10.1212/01.wnl.0000304109.18563.81>
- 651 96. Tamres, L., Janicki, D., Helgeson, V., 2002. Sex Differences in Coping Behavior: A Meta-
652 Analytic Review and an Examination of Relative Coping. *Personality and Social Psychology*
653 *Review - PERS SOC PSYCHOL REV* 6, 2–30.
654 https://doi.org/10.1207/S15327957PSPR0601_1
- 655 97. Taylor, S.E., Klein, L.C., Lewis, B.P., Gruenewald, T.L., Gurung, R.A., Updegraff, J.A.,
656 2000. Biobehavioral responses to stress in females: tend-and-befriend, not fight-or-flight.
657 *Psychol Rev* 107, 411–429. <https://doi.org/10.1037/0033-295x.107.3.411>

- 658 98. Thayer, J.F., Lane, R.D., 2009. Claude Bernard and the heart-brain connection: further
659 elaboration of a model of neurovisceral integration. *Neurosci Biobehav Rev* 33, 81–88.
660 <https://doi.org/10.1016/j.neubiorev.2008.08.004>
- 661 99. Thayer, J.F., Yamamoto, S.S., Brosschot, J.F., 2010. The relationship of autonomic
662 imbalance, heart rate variability and cardiovascular disease risk factors. *Int. J. Cardiol.* 141,
663 122–131. <https://doi.org/10.1016/j.ijcard.2009.09.543>
- 664 100. Tyagi, E., Agrawal, R., Nath, C., Shukla, R., 2010. Cholinergic protection via alpha7
665 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation.
666 *Neurochem. Int.* 56, 135–142. <https://doi.org/10.1016/j.neuint.2009.09.011>
- 667 101. Uher, R., McGuffin, P., 2010. The moderation by the serotonin transporter gene of
668 environmental adversity in the etiology of depression: 2009 update. *Mol. Psychiatry* 15, 18–
669 22. <https://doi.org/10.1038/mp.2009.123>
- 670 102. van der Kooy, K.G., van Hout, H.P.J., van Marwijk, H.W.J., de Haan, M., Stehouwer,
671 C.D.A., Beekman, A.T.F., 2006. Differences in heart rate variability between depressed and
672 non-depressed elderly. *Int J Geriatr Psychiatry* 21, 147–150.
673 <https://doi.org/10.1002/gps.1439>
- 674 103. Verkuil, B., Brosschot, J.F., Marques, A.H., Kampschroer, K., Sternberg, E.M., Thayer, J.F.,
675 2015. Gender differences in the impact of daily sadness on 24-h heart rate variability.
676 *Psychophysiology* 52, 1682–1688. <https://doi.org/10.1111/psyp.12541>
- 677 104. Voss, A., Schroeder, R., Heitmann, A., Peters, A., Perz, S., 2015. Short-term heart rate
678 variability--influence of gender and age in healthy subjects. *PLoS ONE* 10, e0118308.
679 <https://doi.org/10.1371/journal.pone.0118308>
- 680 105. Webb, M., Davies, M., Ashra, N., Bodicoat, D., Brady, E., Webb, D., Moulton, C., Ismail,
681 K., Khunti, K., 2017. The association between depressive symptoms and insulin resistance,
682 inflammation and adiposity in men and women. *PLoS ONE* 12, e0187448.
683 <https://doi.org/10.1371/journal.pone.0187448>

- 684 106. Whooley, M.A., de Jonge, P., Vittinghoff, E., Otte, C., Moos, R., Carney, R.M., Ali, S.,
685 Dowray, S., Na, B., Feldman, M.D., Schiller, N.B., Browner, W.S., 2008. Depressive
686 Symptoms, Health Behaviors, and Risk of Cardiovascular Events in Patients With Coronary
687 Heart Disease. *JAMA* 300, 2379–2388. <https://doi.org/10.1001/jama.2008.711>
- 688 107. Win, S., Parakh, K., Eze-Nliam, C.M., Gottdiener, J.S., Kop, W.J., Ziegelstein, R.C., 2011.
689 Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults:
690 the Cardiovascular Health Study. *Heart* 97, 500–505.
691 <https://doi.org/10.1136/hrt.2010.209767>
- 692 108. World Health Organization. (2017). Depression and other common mental disorders: global
693 health estimates.
- 694 109. Wyman, L., Crum, R.M., Celentano, D., 2012. Depressed mood and cause-specific mortality:
695 a 40-year general community assessment. *Ann Epidemiol* 22, 638–643.
696 <https://doi.org/10.1016/j.annepidem.2012.06.102>
- 697 110. Yang, X., Peng, Z., Ma, Xiaojuan, Meng, Y., Li, M., Zhang, J., Song, X., Liu, Y., Fan, H.,
698 Zhao, L., Deng, W., Li, T., Ma, Xiaohong, 2017. Sex differences in the clinical characteristics
699 and brain gray matter volume alterations in unmedicated patients with major depressive
700 disorder. *Sci Rep* 7, 2515. <https://doi.org/10.1038/s41598-017-02828-4>
- 701 111. Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanan, F., McQueen, M., Budaj,
702 A., Pais, P., Varigos, J., Lisheng, L., INTERHEART Study Investigators, 2004. Effect of
703 potentially modifiable risk factors associated with myocardial infarction in 52 countries (the
704 INTERHEART study): case-control study. *Lancet* 364, 937–952.
705 [https://doi.org/10.1016/S0140-6736\(04\)17018-9](https://doi.org/10.1016/S0140-6736(04)17018-9)
- 706 112. Zellweger, M.J., Osterwalder, R.H., Langewitz, W., Pfisterer, M.E., 2004. Coronary artery
707 disease and depression. *Eur Heart J* 25, 3–9. <https://doi.org/10.1016/j.ehj.2003.09.009>

708




709

710 **Figure 1. Sex differences in cardiac autonomic control of depressed patients.** Depression affects several functional
 711 areas involved in the heart-brain axis. Thus, the cardiovascular autonomic control is altered. Recent studies highlight that
 712 sex influences the relationship between depressive symptoms and cardiac autonomic dysfunction. vmPFC: ventromedial
 713 prefrontal cortex; sgACC: subgenual anterior cingulate cortex; Amy: basolateral amygdala and the central nucleus of the
 714 amygdala; Hyp: hypothalamus (lateral and paraventricular); NTS: nucleus of the solitary tract; RVLM: rostral
 715 ventrolateral medulla; NA: nucleus ambiguus; IML: intermediolateral cell column of the spinal cord.

716

717

718



Adapted from Thayer & Lane (2009)

719

720

721 **Figure 2. The frontal-vagal network and non-invasive neuromodulation techniques.** Non-invasive neuromodulation
 722 techniques, such as repetitive Transcranial Magnetic Stimulation (rTMS), transcranial Direct Current Stimulation (tDCS)
 723 and transcutaneous Vagus Nerve Stimulation (tVNS), modulate the entire frontal-vagal network. The prolonged
 724 stimulation of vagus nerve or prefrontal cortex remodels the depression-damaged neuronal circuits and determines
 725 cardioprotective effects.